April 14th 2021
Opinions are diverse on how best to clear the obstructions to biosimilar market entry and patient access.
April 9th 2021
The latest e-book from The Center for Biosimilars® offers insightful content on patient education, biosimilar development, and regulatory issues.
April 7th 2021
Richard G. Frank, PhD, and Meaghan Rose Smith discuss a recent white paper on the regulatory and anticompetitive impediments to biosimilar market entry and the hope for biosimilar savings.
March 24th 2021
By Tony Hagen
The company claims in a suit that a former employee transferred high-concentration adalimumab trade secrets to his laptop and took those to a new job with Alvotech.
March 16th 2021
"Shocked" by the threat of competition, originator manufacturers start raising prices long before rival products appear on the scene, investigators found.
March 12th 2021
The Biologics Price Competition and Innovation Act has been around for 10 years, but grey legal areas still abound, Goodwin attorneys note.
March 7th 2021
Key 2020-2021 updates to the Guide to Biosimilars litigation and Regulation in the US encompass antitrust litigation, preliminary injunctions, and a slowdown in litigation.
March 6th 2021
Minnesota legislators introduce what could possibly become the first law to curtail payers' rights to determine which biologics patients have access to.
February 20th 2021
Huiya Wu, JD, and Freddy Yip, PhD, PCLL, attorneys at Goodwin Procter, discussed projections for the Chinese biosimilars market and the potential for foreign companies to get a share.
February 17th 2021
Huiya Wu, JD, and Freddy Yip, PhD, PCLL, attorneys at Goodwin Procter, discussed biologic drug patent laws in China and the US.
